Stephen Karimi
Family · Statesboro, GANPI 1245782325
Payments from drug & device makers
Across 149 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$622
- Travere Therapeutics, Inc.$575
- Amgen$459
- Vifor Pharma, Inc.$454
- Bayer$363
- OPKO Pharmaceuticals, LLC$316
- plus $815 from 8 others
What the payments were for
- Food & beverage$3,38494%
- Education$2206%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $622 |
| Travere Therapeutics, Inc. | 22 | $575 |
| Amgen(2 entities) | 20 | $459 |
| Vifor Pharma, Inc. | 17 | $454 |
| Bayer | 10 | $363 |
| OPKO Pharmaceuticals, LLC | 16 | $316 |
| Calliditas Therapeutics US Inc. | 11 | $272 |
| Otsuka America Pharmaceutical, Inc. | 7 | $258 |
| Ardelyx, Inc. | 4 | $122 |
| Novo Nordisk | 3 | $60 |
| Fresenius USA Marketing, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $30 |
| Dexcom, Inc. | 1 | $20 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,604 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 13 | $370,828 |
| FarxigaDapagliflozin Propanediol | 28 | $17,340 |
| JardianceEmpagliflozin | 14 | $8,009 |
| Sevelamer Carbonate | 19 | $3,040 |
| ProsolParenteral Amino Acid 20% No.1 | 14 | $1,617 |
| Calcitriol | 67 | $868 |
| Hydralazine Hcl | 43 | $393 |
| Buspirone Hcl | 44 | $345 |
| Midodrine Hcl | 12 | $297 |
| Losartan Potassium | 40 | $259 |
| Potassium Chloride | 24 | $226 |
| Furosemide | 54 | $188 |
| Carvedilol | 34 | $114 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 13 | $97 |
| Clonidine Hcl | 23 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $459 | $370,82813 claims |
| AstraZenecaFarxiga | $622 | $17,34028 claims |
| Boehringer IngelheimJardiance | $30 | $8,00914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Statesboro
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.